( NASDAQ-SMALL:APPY )

News from venaxis, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Mar 14, 2016, 17:00 ET Venaxis Announces Termination of Proposed Transactions with Strand Life Sciences

Venaxis®, Inc. (Nasdaq: APPY), announced today that Venaxis, Strand Life Sciences Private Limited (Strand LS) and its U.S. subsidiary Strand...


Jan 26, 2016, 16:10 ET Venaxis Announces Transaction with Strand Life Sciences

Venaxis®, Inc. (Nasdaq: APPY), announced today that it has entered into a series of agreements for a transaction with Strand Life Sciences...


Jun 22, 2015, 16:05 ET Venaxis Business Update

 Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked...


Apr 06, 2015, 09:00 ET Venaxis to Provide Business Update

Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1™...


Feb 12, 2015, 09:00 ET Venaxis Business Update

 Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked...


Jan 29, 2015, 06:25 ET Venaxis Receives FDA "Not Substantially Equivalent" Response on APPY1 510(k) Submission

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1™...


Jan 06, 2015, 16:10 ET Venaxis, Inc. to Present at Biotech Showcase™ 2015

 Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked...


Dec 03, 2014, 16:35 ET Venaxis Files Response to FDA's Request for Additional Information

 Venaxis®, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE...


Nov 13, 2014, 16:15 ET Venaxis to Present at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE...


Oct 27, 2014, 16:30 ET Venaxis' APPY1 Trial Results Presented by Dr. David S. Huckins, M.D., at ACEP14

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE...


Oct 14, 2014, 16:05 ET Venaxis Announces APPY1 Test Clinical Trial Results to be Presented at ACEP14

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE...


Aug 28, 2014, 09:15 ET Venaxis to Present at September Investor Conferences

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE...


Aug 11, 2014, 08:10 ET Venaxis Announces Regulatory and Market Development Progress

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked...


Aug 07, 2014, 16:15 ET Venaxis to Provide Business Update, including FDA Submission Update

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked...


Aug 05, 2014, 16:15 ET Venaxis to Present at Canaccord Genuity 34th Annual Growth Conference

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™...


Jul 16, 2014, 09:15 ET Venaxis Reports on Recent FDA Submission Activities

CASTLE ROCK, Colo., July 16, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA...


Jul 01, 2014, 16:10 ET Venaxis to Present at ICV Company Outreach Summit

Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™...


May 21, 2014, 16:15 ET Venaxis to Participate in 11th Annual Craig-Hallum Institutional Investor Conference

Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1™...


Apr 08, 2014, 16:01 ET Venaxis, Inc. Closes Public Offering of Common Shares

 Venaxis, Inc. (NASDAQ:APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked...


Apr 03, 2014, 09:00 ET Venaxis, Inc. Prices $20.0 Million Public Offering of Common Shares

 Venaxis, Inc. (NASDAQ: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked...


Apr 02, 2014, 16:01 ET Venaxis, Inc. Announces Proposed Public Offering of Common Shares

Venaxis, Inc. (NASDAQ: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™...


Mar 31, 2014, 07:30 ET Venaxis Files for FDA Clearance of APPY1 Test

CASTLE ROCK, Colo., March 31, 2014 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA...


Mar 13, 2014, 07:00 ET Venaxis Announces Positive Top-Line Results from Pivotal Study of APPY1 Test

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked...


Mar 12, 2014, 17:15 ET Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test

Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™...


Jan 24, 2014, 07:33 ET Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1™ Test

 Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1...